Commentary on “Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects”-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Commentary on “Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects”

Published:2024-08 Issue: Volume:206 Page:107267
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Wang Yuning,Zhao Guo,Xing Shujun,Wang Shuhang,Li Ning

Funder

National Natural Science Foundation of China

Beijing Municipal Health Commission

Chinese Academy of Medical Sciences & Peking Union Medical College

National Key Research and Development Program of China

Publisher

Elsevier BV

Reference7 articles.

1. Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects;Zhu;Pharm. Res,2024

2. Breaking through the treatment desert of conventional mesothelin-targeted CAR-T cell therapy for malignant mesothelioma: a glimpse into the future;Wang;Pharm. Res,2024

3. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells;Haas;Mol. Ther.,2023

4. Development of highly effective anti-mesothelin hYP218 chimeric antigen receptor T cells with increased tumor infiltration and persistence for treating solid tumors;Tomar;Mol. Cancer Ther.,2022

5. Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope;Liu;Proc. Natl. Acad. Sci. USA,2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP